Corporate Banner
Satellite Banner
Genomics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Genticel Launches its Phase II Trial in Women Infected with High-Risk HPV

Published: Thursday, March 06, 2014
Last Updated: Thursday, March 06, 2014
Bookmark and Share
The appointment of Dr. Sophie Olivier as chief medical officer completes the Genticel team to run the Phase II trial across Europe.

Genticel has announced that it has started a phase II study with its lead product ProCervix, a therapeutic vaccine designed to induce a curative cellular immune response in patients infected with HPV16 and/or HPV18. The high-risk human papillomavirus HPV16 and/or HPV18 types are responsible for 70 per cent of cervical cancers worldwide.

ProCervix is targeted at women already infected by the HPV16 and/or HPV18 viruses before high-grade lesions or cancer occur. It is the first therapeutic vaccine to address the medical need of this high-risk population, because the preventive HPV vaccines are only effective in people who are not yet infected.

The Phase I study was conducted at the Vaccine and Infectious Disease Institute of the University of Antwerp, Belgium under the direction of Professor Pierre Van Damme. The results indicated that ProCervix has a satisfactory safety, local tolerance and immunogenicity profile.

This study revealed the dose and vaccination regime required for further development. The clearance of HPV virus and maintenance of virus-free status was also markedly higher in the patients treated with ProCervix versus those in the placebo group.

Based on these promising results with ProCervix, endorsed by an international group of experts, Genticel has initiated a randomized, placebo-controlled efficacy Phase II trial. This multi-centric trial has received favorable scientific advice from the European Medical Agency (EMA) and runs across several European countries.

Dr. Sophie Olivier appointed as chief medical officer
Genticel has recruited Dr. Sophie Olivier as chief medical officer to lead the clinical development of its pipeline, in particular the ProCervix phase II trial. Dr. Olivier has over 20 years of experience in gynecology, women’s health and regulatory affairs.

Dr. Sophie Olivier was scientific administrator at the European Medicines Agency (EMA) in London, UK. She was responsible for assessing Pediatric Investigational Plans, in particular vaccines. Prior to EMA, Dr. Olivier also worked for 15 years with Wyeth.

As a senior director, Women’s Health and Bone Repair, she was responsible for designing and implementing international clinical development programs in women’s health, leading to FDA and European submissions.

Dr. Olivier is an MD from Aix-Marseille University. She also holds a Master’s degree in Reproductive Biology and a Science and Statistics Masters from Pierre and Marie Curie University - Paris VI.

“We are very pleased to welcome Dr. Olivier. Her expertise in drug development, especially in vaccines and gynecology, and her experience at the EMA are considerable assets for Genticel, in particular for the ProCervix Phase II trial,” said Benedikt Timmerman, CEO of Genticel. “ProCervix is a first-in-class therapeutic HPV vaccine aimed at treating HPV infected women for whom no therapeutic options currently exist and with only ‘watchful waiting’ as an alternative.”

“I am thrilled to join the team at Genticel and to work on the development of these promising therapeutic vaccines,” said Dr. Olivier. “The phase I for the therapeutic candidate vaccine was successful and I look forward to pursuing its development in Europe and abroad.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,200+ scientific posters on ePosters
  • More than 4,800+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Genticel Secures EUR 18.2 Million (USD 23.7 million) in Capital Funding
Dr. Rainer Strohmenger joins the supervisory board of Genticel.
Friday, April 26, 2013
Scientific News
Liquid Biopsies: Miracle Diagnostic or Next New Fad?
Thanks to the development of highly specific gene-amplification and sequencing technologies liquid biopsies access more biomarkers relevant to more cancers than ever before.
New Therapeutic Targets For Small Cell Lung Cancer Identified
Researchers at UTSW Medical Center have identified a protein termed ASCL1 that is essential to the development of small cell lung cancer and that, when deleted in the lungs of mice, prevents the cancer from forming.
Deciphering Inactive X Chromosomes
Untangling the Barr body of inactive X chromosomes valuable for understanding chromosome structure and gene expression.
Micro Disease-Detecting Senor Created
Researchers at McMaster University have created a microscopic disease-detecting sensor that can turn on to detect trace amounts of substances.
Liquid Biopsies Treating Ovarian Cancer
Researchers have discovered a promising monitor and treat recurrence of ovarian cancer. Detecting cancer long before tumours reappear.
Uncovering a New Principle in Chemotherapy Resistance in Breast Cancer
The NIH study has revealed an entirely unexpected process for acquiring drug resistance that bypasses the need to re-establish DNA damage repair in breast cancers that have mutant BRCA1 or BRCA2 genes.
Understanding Treatment Resistant Melanoma
Researchers have determined how advanced melanoma becomes resistant; a development toward developing treatments.
Investigating ‘Black Box’ of Human Genetics
Investigations into inactive X chromosomes have shown unusual DNA repeat elements are essential for maintaining 3D structure.
Liquid Biopsies: DNA Size Matters
Study finds circulating tumour DNA can be distinguished from healthy DNA through fragment size identification.
Protein Teams Activate T-Cells
Caltech researchers have discovered T-cell genetic switching is controlled by four proteins acting in a multi-tiered fashion.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,200+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,800+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!